Literature DB >> 8675330

Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus.

S J Devi1, U Hayat, J L Powell, J G Morris.   

Abstract

Vibrio vulnificus is an oyster-associated bacterial pathogen that causes life-threatening fulminating septicemia and necrotizing wound infections in humans. The capsular polysaccharide of V. vulnificus (VvPS) is critical for virulence. Previously we showed that active immunization of mice with a VvPS-tetanus toxoid (VvPS-TTa) conjugate vaccine conferred significantly higher protection against subsequent lethal challenge than immunization with VvPS alone. In the current study, we examined the utility of immunoprophylaxis or immunotherapy with hyperimmune antisera elicited by VvPS-TTa and VvPS-TTb conjugate vaccines prepared by different synthetic schemes. First we demonstrated that the Ribi adjuvant significantly enhanced the murine antibody response (P < or = 0.02) to both conjugates. Subsequently, high-titered polyclonal antisera were raised to VvPS-TTa and VvPS-TTb conjugate vaccines by using Ribi adjuvant or Freund's adjuvants. Antisera were observed to have protective effects when administered before and after acute lethal infection. All animals receiving prophylactic antisera intraperitoneally 24 h before lethal challenge with homologous carbotype 1 were protected, while 73 to 100% of control mice succumbed. Immunotherapy was also effective, with survival rates of 60 to 73% seen among mice when antisera were administered 2 h after bacterial challenge, at a time when symptoms of infection were already apparent. The protective effect of capsular antiserum appeared to be serotype specific. Antisera to the, carbotype 1 VvPS-TTa vaccine did not confer cross-protection against lethal challenge with carbotype 2 V. vulnificus despite partial structural similarity and a weak serological cross-reaction between the two carbotypes. Immune globulins induced by a potential multivalent VvPS conjugate vaccine composed of clinically prevalent carbotypes may have utility in the management of V. vulnificus infections and deserve further evaluation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675330      PMCID: PMC174059          DOI: 10.1128/iai.64.6.2220-2224.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Correlation between virulence and colony morphology in Vibrio vulnificus.

Authors:  L M Simpson; V K White; S F Zane; J D Oliver
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

Review 2.  Vibrio vulnificus--a new monster of the deep?

Authors:  J G Morris
Journal:  Ann Intern Med       Date:  1988-08-15       Impact factor: 25.391

3.  Production and partial characterization of an elastolytic protease of Vibrio vulnificus.

Authors:  M H Kothary; A S Kreger
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

4.  Inhibitory effect of capsular antigen of Vibrio vulnificus on bactericidal activity of human serum.

Authors:  S Shinoda; M Kobayashi; H Yamada; S Yoshida; M Ogawa; Y Mizuguchi
Journal:  Microbiol Immunol       Date:  1987       Impact factor: 1.955

5.  Vibrio vulnificus (lactose-positive vibrio) and Vibrio parahaemolyticus differ in their susceptibilities to human serum.

Authors:  M M Carruthers; W J Kabat
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

6.  Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987.

Authors:  K C Klontz; S Lieb; M Schreiber; H T Janowski; L M Baldy; R A Gunn
Journal:  Ann Intern Med       Date:  1988-08-15       Impact factor: 25.391

7.  Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis.

Authors:  G R Siber; D M Ambrosino; J McIver; T J Ervin; G Schiffman; S Sallan; G F Grady
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

8.  Clinical features and an epidemiological study of Vibrio vulnificus infections.

Authors:  C O Tacket; F Brenner; P A Blake
Journal:  J Infect Dis       Date:  1984-04       Impact factor: 5.226

9.  Vibrio vulnificus infection after raw oyster ingestion in a patient with liver disease and acquired immune deficiency syndrome-related complex.

Authors:  K P Chin; M A Lowe; M J Tong; A L Koehler
Journal:  Gastroenterology       Date:  1987-03       Impact factor: 22.682

10.  Mouse skin damage caused by cytolysin from Vibrio vulnificus and by V. vulnificus infection.

Authors:  L D Gray; A S Kreger
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

View more
  7 in total

1.  Differential expression of Vibrio vulnificus capsular polysaccharide.

Authors:  A C Wright; J L Powell; M K Tanner; L A Ensor; A B Karpas; J G Morris; M B Sztein
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Monoclonal antibodies against Vibrio vulnificus RtxA1 elicit protective immunity through distinct mechanisms.

Authors:  Tae Hee Lee; Sun-Shin Cha; Chang-Seop Lee; Joon Haeng Rhee; Kyung Min Chung
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

Review 3.  Immune response and immunotherapy to Cryptococcus infections.

Authors:  Qing Zhou; William J Murphy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  The pyrH gene of Vibrio vulnificus is an essential in vivo survival factor.

Authors:  Shee Eun Lee; Soo Young Kim; Choon Mee Kim; Mi-Kwang Kim; Young Ran Kim; Kwangjoon Jeong; Hwa-Ja Ryu; Youn Suhk Lee; Sun Sik Chung; Hyon E Choy; Joon Haeng Rhee
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

5.  Identification of a group 1-like capsular polysaccharide operon for Vibrio vulnificus.

Authors:  A C Wright; J L Powell; J B Kaper; J G Morris
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Release of tumor necrosis factor alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models.

Authors:  J L Powell; A C Wright; S S Wasserman; D M Hone; J G Morris
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

7.  Total Synthesis of the Tetrasaccharide Haptens of Vibrio vulnificus MO6-24 and BO62316 and Immunological Evaluation of Their Protein Conjugates.

Authors:  Han Zhang; Xiaohan Wang; Youhui Meng; Xiaoyu Yang; Qingpeng Zhao; Jian Gao
Journal:  JACS Au       Date:  2021-11-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.